INSM

[MARTY]

 I am looking to buy one of these 3 stocks.  After much research I am still not sure which is the one.  All 3 seem to have great things going.  Anyone have any suggestions? Are you holding these? What are your thoughts?

[terabemo]

INSM BREAKING OUT!!!!


COULD GO OVER $2 EASILY AFTER THE ENDO PRESENTATIONS  LATE THIS WEEK AND MONDAY

[la-onda]

please check the FRPT Subject & Analysis via Search Functionality 

cheers
Oliver

[terabemo]

 

[terabemo]

Fundamentals and Technicals are coming together at the right time.

TA traders will like the chart and will start joining in the buying frenzy that is about to get started.

[D&Data]

Guys...
News out :

Read it... ( and happy to know that Iplex could BE used in several sides )

Insmed Endocrine Society 2006 Update
Thursday June 22, 8:04 am ET 
Insmed Will Report Efficacy of IPLEX(TM) in Patients with Severe Insulin Resistance
Company Also to Present Data on the Unique Pharmacokinetics of IPLEX


RICHMOND, Va.--(BUSINESS WIRE)--June 22, 2006--Insmed, Inc (NASDAQ: INSM - News) today announced that investigators from the University of Cambridge, UK, will be presenting new results on the safety and efficacy of its insulin-like growth factor drug, IPLEX(TM) (mecasermin rinfabate (rDNA origin) injection), in patients with severe insulin resistance syndromes at the annual meeting of the Endocrine Society in Boston, MA. This platform presentation will be given on Tuesday, June 27 at 11:30 a.m., Room 206 of the Boston Convention and Exhibit Center. The title of the talk is:
rhIGF-1/rhIGFBP-3 Treatment of Patients with Severe Insulin Resistance Syndromes: Preliminary Data, Fiona Regan, Marc de Kerdanet, Mehul Dattani, Andreas Sommer, Kenneth M Attie, David B Dunger. (ENDO Abstract OR40-2)
Insmed also will be presenting additional data demonstrating the safety and efficacy of IPLEX on patients with severe IGF-I deficiency. In addition, two posters will highlight the attributes of IPLEX's pharmacokinetic profile. Studies to be presented include:

Once Daily rhIGF-1/rhIGFBP-3 Treatment Improves Growth in Children with Severe Primary IGF-I Deficiency: Results of a Multicenter Clinical Trial (ENDO Abstract OR40-1, Tuesday, June 27, 11:15 a.m., room 206, Boston Convention and Exhibit Center)
Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers Does Not Result in Supraphysiological Concentrations of Free IGF-I (ENDO Abstract P1-192, Saturday June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
Pharmacokinetics of Single Dose Subcutaneous Administration of rhIGF-1/rhIGFBP-3 in Healthy Adult Volunteers (ENDO Abstract P1-191, Saturday, June 24, 11 a.m., poster session, Boston Convention and Exhibit Center)
"We are extremely pleased to be presenting data at two poster and two podium presentations. We believe that IPLEX is a breakthrough drug that is showing very promising results in patients with severe insulin resistance. The preliminary data that will be presented at ENDO 2006 show that IPLEX may be beneficial for treating these patients, who are generally unresponsive to conventional therapies," remarked Kenneth M. Attie, M.D., Vice President, Medical Affairs, Insmed. "Additional data being presented supports the rationale for developing a unique dual protein therapeutic to closely mimic normal human physiology."

IPLEX is approved in the United States for the treatment of growth failure in children with severe primary IGF-I deficiency (Primary IGFD).

cheers
D.

[terabemo]

INSM ROCKS!!!

[jorgegr]

This time you are in track.
After yesterday's white candle breakout from the falling
trend, could be a reversal and shorts covering will help.

Good luck to those holding.

jorgegr

[terabemo]

Buying on the dips....

[calven]

Chart looks MUCH BETTER! 

[terabemo]

We could have a nice rally this afternoon. I wouldn't be surprised to see $1.7 - $1.8 today.

Good luck

[D&Data]

INFORMATION  :


SIR podium pres. monday @ 11:30AM
by: l_oompa (40/,)
Long-Term Sentiment: Strong Buy  06/23/06 09:01 am
Msg: 109724 of 109724

...and 2 poster sessions in the weekend. Not too much time left to buy some cheap shares.

Off-label implications for using IPLEX for athletes and adults and SIR phII results & "the rationale for developing a unique dual protein therapeutic" for T1DM, will make this stock soar.

time to load ....

D.

[terabemo]

I agree 100%

[terabemo]

I guessed correctly this time. It closed at $1.73.

Next week will be interesting.....

[la-onda]

good luck, TA is positive IMO